Claims for Patent: 7,163,698

Summary for Patent: 7,163,698

Title:	Controlled drug delivery system using the conjugation of drug to biodegradable polyester
Abstract:	The present invention relates to the molecular sustained controlled release system constructed by the conjugation of molecules to be released with biodegradable polyester polymer via covalent bond and method for preparation thereof. In accordance with the present invention, the system may be formulated into microspheres, nanoparticles, or films. The molecular release rate from the above system can be regulated to be proportional to the chemical degradation rate of the biodegradable polyester polymers, resulting in near zero order kinetics profile of release without showing a burst effect. Moreover, the high loading efficiency of hydrophilic drugs can be achieved.
Inventor(s):	Oh; Jong Eun (Socho-ku, Seoul, 137-767, KR), Lee; Keon Hyoung (Mapo-ku, Seoul, 121-110, KR), Park; Tae Gwan (Yusong-ku, Taejon-si, 305-390, KR), Nam; Yoon Sung (Songpa-ku, Seoul, 138-789, KR)
Assignee:
Application Number:	10/423,536
Patent Claims:	1. A sustained controlled release system consisting of a drug molecule to be released directly conjugated to a biodegradable polyester polymer via a covalent bond, wherein the conjugation is carried out after activating the biodegradable polyester polymer by mixing with coupling agents, bases and optionally additives, wherein the coupling agents are selected from the group comprising bis(2-oxo-3-oxazolydinyl)phosphonic chloride (BOP-Cl), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP), benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate (HBTU), dicyclohexyl carbodiimide, disuccinimidyl carbonate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), bis(2-oxo-3-oxazolydinyl)phosphin, diisopropyl carbodiimde (DIPC), 2-(1H-benzotrioxazolyl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate (TBTU), 2-(5-norboren)-2,3-dicarboxyimido)-1,1,3,3-tetramethyluronium tetrafluoroborate (TNTU), para-nitrophenylchloroformate, and O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU), and wherein the bases are selected from the group consisting of triethylamine, N-methylmorpholine, pyridine, 1,8-diazabicyclo[5,4,0]-undec-7-ene, N,N-dimethyl aminopyridine, and N,N-diisopropyl ethylamine. 2. The system of claim 1, wherein the conjugate of the drug molecule with the biodegradable polyester polymer is formulated into microspheres, nanoparticles, or films. 3. The system of claim 2, wherein the microspheres are about 1 to about 300 .mu.m in size. 4. The system of claim 2, wherein the nanoparticles are about 50 to about 1000 nm in size. 5. The system of claim 1, wherein, the biodegradable polyester polymer is selected from the group consisting of poly(lactic acid), poly(glycolic acid), poly(D-lactic-co-glycolic acid), poly(L-lactic-co-glycolic acid), poly(D,L-lactic-co-glycolic acid), poly(caprolactone), poly(valerolactone), poly(hydroxybutyrate), poly(hydrovalerate), polydioxnanone, and their derivatives. 6. The system of claim 1, wherein the biodegradable polyester polymer has a molecular weight from about 1000 Da to about 100000 Da. 7. The system of claim 1, wherein the biodegradable polyester polymer is a poly(lactic-co-glycolic acid) with the ratio of lactic acid and glycolic acid ranging from 1:10 to 10:1. 8. The system of claim 1, wherein the conjugate of the drug molecule with the biodegradable polyester polymer is employed via ester bond, amide bond, anhydride bond, carbonate bond, imine bond, thioester bond, urea bond, urethane bond, disulfide bond, or carbamate bond. 9. The system of claim 1, wherein the drug molecule is a biologically active compound selected from the group consisting of peptides, proteins, therapeutic agents, diagnostic agents, and non-biological materials. 10. The system of claim 9, wherein the peptides are selected from the group consisting of insulin, calcitonin, ACTH, glucagon, somatostatin, somatotropin, somatomedin, parathyroid hormone, erythropoietin, hypo-thalmic releasing factors, prolactin, thyroid stimulating hormone, endorphins, enkephalins, vasopressin, non-naturally occurring opioids, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, trypsin, chemotrypsin, and pepsin. 11. The system of claim 9, wherein the therapeutic agents comprise anticancer agents selected from the group consisting of dideoxyinosine, floxuridine, 6-mercaptopurine, doxorubicin, daunorubicin, I-darubicin, cisplatin, methotrexate, prodrugs thereof, and derivatives thereof. 12. The system of claim 9, wherein the therapeutic agents comprise antibiotics selected from the group consisting of erythromycin, vancomycin, oleandomycin, ampicillin, prodrugs thereof, and derivatives thereof. 13. The system of claim 9, wherein the therapeutic agents are anticoagulant, prodrugs thereof, or derivatives thereof. 14. The system of claim 13, wherein the anticoagulant is heparin. 15. The system of claim 9, wherein the therapeutic agents comprise germicides selected from the group consisting of ara-A, acrylguanosine, nordeoxyguanosine, azidothymidine, dideoxyadenosine, dideoxythymidine, prodrugs thereof, and derivatives thereof. 16. The system of claim 9, wherein the therapeutic agents are antiarrhythmic agent, prodrugs thereof, or derivatives thereof. 17. The system of claim 9, wherein the non-biological materials are selected from the group consisting of pesticides, herbicides, and fertilizers. 18. The system of claim 1, wherein the additives are selected from the group consisting of hydroxybenzotriazole, pentafluorophenol and N-hydroxy-5-norboren-endo-2,3-dicarboximide.

Details for Patent 7,163,698

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2018-05-16
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2018-05-16